Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0642-1895 · 1 trial · 1 indication
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0642-1895 | EXPERIMENTAL | Participants will be administered a single dose of NNC0537-1482 intravenously. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC0642-1895 intravenously. |
| Name | Type | Description |
|---|---|---|
| NNC0642-1895 | DRUG | NNC0642-1895 will be administered intravenously. |
| Placebo | DRUG | Placebo will be administered intravenously. |
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 to 29.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening * Consider...
NNC0642-1895 is an investigational small molecule drug being developed by Novo Nordisk A/S. It is in Phase 1 clinical development and is being studied in healthy volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed.
NNC0642-1895 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this investigational small molecule.
NNC0642-1895 is in Phase 1 clinical development. It is an investigational drug and is not approved for any use. Its only registered study is a Phase 1 trial in healthy volunteers that is currently recruiting participants.
NNC0642-1895 is being studied in one clinical trial, NCT07829406, titled a study to see how safe a new medicine (NNC0642-1895) is in healthy people. The Phase 1 trial is recruiting 148 healthy adult volunteers in the United States and is randomized, double-blind, and placebo-controlled.
NCT07829406 is a Phase 1 study evaluating the safety of NNC0642-1895 in healthy volunteers. It is a randomized, double-blind, placebo-controlled trial enrolling 148 participants aged 18 years and older in the United States, and it is currently recruiting.